The MealCam blog
Eat the meal.
Notice the moment.
Practical, evidence-aware writing about rushed eating, attention, and why we built a speedometer for meals instead of another food diary. Search for a drug, a book or a habit, or narrow it by subject.
58 articles
Zepbound for Teens: SURMOUNT-ADOLESCENTS Cuts BMI 18.5% (2026)
Zepbound in teens (JAMA, Nov 15, 2026): BMI fell 18.5% vs a 0.5% rise on placebo over 72 weeks, counting everyone. Side effects, Wegovy, approval.
Lower-Dose CagriSema: About 19% Weight Loss in REDEFINE 9 (2026)
In REDEFINE 9 (Nov 14, 2026), lower-dose CagriSema cut weight 18.6–19.4% in 68 weeks vs 4.6% on placebo, counting everyone. How it compares with Wegovy.
Ozempic Vision Loss Warning: FDA Adds NAION to All GLP-1s (2026)
FDA, Nov 9, 2026: every GLP-1, from Ozempic to Zepbound, gets a NAION vision-loss warning. In trials: 6.4 vs 3.8 cases per 100,000 patient-years.
Foundayo for Sleep Apnea: ATTAIN-OSA Trial Results in JAMA (2026)
Foundayo (orforglipron) cut sleep apnea events by 17 to 18 an hour vs about 5 on placebo in two 52-week ATTAIN-OSA trials (JAMA, Nov 9, 2026). How it compares.
Retatrutide Knee Osteoarthritis Results: TRIUMPH-4 in NEJM (2026)
Retatrutide cut knee osteoarthritis pain 3.96 vs 2.12 points on placebo and weight 20.0% vs 4.6% in TRIUMPH-4 (NEJM, Nov 8, 2026). What it means, what's next.
Pelacarsen Lp(a)HORIZON Results: Lp(a) Fell 78%, Events Didn't (2026)
Pelacarsen cut Lp(a) 78% in the Lp(a)HORIZON trial (NEJM, Nov 7, 2026), but heart events were 12.3% vs 12.1% on placebo. What it means if your Lp(a) is high.
How to Lie with Statistics Summary: Huff's Tricks in Health Ads
How to Lie with Statistics by Darrell Huff, summarized: his tricks paired with real drug, food and supplement examples, plus 5 questions to check any claim.
GLP-1 Plateau: Why Weight Loss Stalls on Zepbound or Wegovy (2026)
A GLP-1 plateau is expected: in trials, weight loss on Wegovy and Zepbound leveled off around weeks 60–72. Why it happens and what to check before you worry.
Viking Therapeutics Q3 2026: When Will VK2735 Be Available?
Viking Therapeutics Q3 2026: VK2735's Phase 3 shot trials are full and due in 2027, a pill trial began, monthly-dose data, and why launch is years away.
GLP-1 Constipation: Why It Happens and What Experts Advise (2026)
GLP-1 constipation hits 11% to 27% of people on Zepbound, Wegovy or Foundayo. Why it happens, the steps experts recommend, and the red flags to call about.
Regeneron Q3 2026 Earnings: Its Obesity Bet Is Muscle, Not Pounds
Regeneron's Q3 2026 earnings: $5.1B revenue, none from obesity. Its weight-loss bet is olatorepatide plus Praluent and muscle-saving trevogrumab.
Eli Lilly Q3 2026 Earnings: What It Means for Zepbound and Foundayo
Lilly's Q3 2026 earnings call: Zepbound and Mounjaro hit $16.1B, Foundayo $184M, and 500,000+ got Lilly drugs via Medicare's $50 Bridge. What it means.
What Happens When You Stop Zepbound or Wegovy? The Regain Data (2026)
Stopping a GLP-1? In the STEP 1 trial, people regained about two-thirds of the weight a year after stopping semaglutide. The numbers, and a plan to make first.
Glucose Revolution Summary: The 10 Glucose Goddess Hacks, Fact-Checked
Glucose Revolution by Jessie Inchauspé, summarized: all 10 Glucose Goddess hacks, which ones research backs, which are overstated, and a day to copy.
The 2026 Weight-Loss Drug Pipeline: Every GLP-1 and Amylin Drug, Ranked
Every major weight-loss drug in the 2026 pipeline, ranked: Zepbound, Foundayo, CagriSema, retatrutide, EloraTZP and more, sorted by when you can get them.
Cagrilintide vs Eloralintide: The Two Amylin Shots Compared (2026)
Cagrilintide vs eloralintide: eloralintide hit 20.1% weight loss at 48 weeks, cagrilintide alone 11.8% at 68 weeks. Every trial compared, plus the caveat.
Tradipitant for GLP-1 Nausea and Vomiting: Phase 3 Results (2026)
Tradipitant for GLP-1 vomiting: in Phase 3, 43% vomited vs 58.5% on placebo after one untitrated semaglutide dose. What it means and what's unknown.
Amylin Drugs Explained: The “Fullness Hormone” Behind EloraTZP
Amylin drugs explained: how the fullness hormone differs from GLP-1, why eloralintide hit 20.1% alone, and which amylin drugs, like CagriSema, come first.
Eloralintide Phase 3: ENLIGHTEN-10 Adds a 3,000-Person Trial (2026)
Eloralintide Phase 3: Lilly's ENLIGHTEN-10 tests it against placebo in 3,000 adults with type 2 diabetes and heart risk. What it measures and when.
Retatrutide Brand Name: Are Retkouro and Retzoundi Real? (2026)
Retatrutide brand name: Retkouro and Retzoundi are real Lilly trademark filings from 2024, but Lilly hasn't named the drug. What the records show.
Retatrutide vs Ozempic: 20.9% vs 9.4% Weight Loss Head to Head (2026)
Retatrutide vs Ozempic: in an 80-week head-to-head trial in type 2 diabetes, retatrutide cut weight 20.9% vs 9.4% if all stayed on treatment. What it means.
Eating Too Fast on Ozempic? Why Pace Matters More Than Ever
Eating too fast on Ozempic can backfire. A classic study found slow eating raised natural GLP-1 by 41%. Why pace matters on semaglutide, plus 3 habits.
Outlive Summary: Peter Attia’s Longevity Plan, and Its Limits
Outlive by Peter Attia, summarized: the Four Horsemen, why fitness may matter most, the centenarian decathlon, protein, apoB, and where critics push back.
The New Menopause Summary: Mary Claire Haver’s Toolkit, Explained
The New Menopause by Dr. Mary Claire Haver, summarized: why hot flashes can last 7+ years, what changed on hormone therapy, her symptom toolkit, and its limits.
Why You Feel Full Faster on Zepbound, and How to Listen to It
Why you feel full faster on Zepbound: how tirzepatide slows your stomach and quiets food noise, why fullness still arrives late, and a simple check.
How to Eat on GLP-1s: Slow Down, Stop at Full, Skip the Nausea
How to eat on GLP-1s like Wegovy, Zepbound, and Foundayo: six simple rules for smaller meals, protein first, slower eating, and fewer queasy afternoons.
The Hunger Code Summary: Jason Fung’s 3 Rules for Taming Hunger
The Hunger Code by Jason Fung, summarized: 3 types of hunger, the fat thermostat, his 3 Golden Rules, what studies say on fasting and GLP-1s, and its limits.
Foundayo Side Effects: What the Label and Trials Show (2026)
Foundayo side effects by dose: nausea in 26–35%, quit rates, the new FDA eye (NAION) warning, the 30-day birth control rule, and when to call a doctor.
Ultra-Processed People Book Summary: How to Spot Ultra-Processed Food
Ultra-Processed People by Chris van Tulleken, summarized: what counts as ultra-processed food, a 10-second label test, what the studies show, and its limits.
CagriSema vs EloraTZP: The Amylin Combo Showdown (2026)
CagriSema vs EloraTZP: 22.7% vs 23.3% weight loss, the fair type 2 diabetes comparison, quit rates, and which amylin combo reaches pharmacies first.
CagriSema in Women: What the 25% Weight-Loss Data Really Shows (2026)
Women on CagriSema lost 25% of body weight on average in REDEFINE 1, across menopause stages. Plus what new studies show about hormone therapy and GLP-1s.
Skinny Liver Book Summary: The Fatty Liver Diet Plan, Explained
Skinny Liver by Kristin Kirkpatrick and Ibrahim Hanouneh, summarized: the 4-week fatty liver diet plan, what newer science backs, and what changed since 2017.
EloraTZP Phase 3: What the AMPLIFY Trials Will Test, and When (2026)
EloraTZP hit up to 23.3% weight loss in Phase 2. Now AMPLIFY-1 (2,115 people) and AMPLIFY-2 take on Zepbound's drug head to head. What they test, and when.
When Will Retatrutide Be Available? Release Date, Cost & FDA Timeline
When will retatrutide be available? Lilly plans to file with the FDA in Q1 2027. The likely approval window, early access, cost, and online “reta” risks.
Foundayo vs Zepbound: Pill or Shot, Which Works Better? (2026)
Foundayo vs Zepbound compared: 12.4% vs 20.9% weight loss, $149 vs $299+ a month, side effects and quit rates. A plain-English guide to pill vs shot.
Retatrutide for Sleep Apnea: What the NEJM Trials Found (2026)
Retatrutide sleep apnea results: AHI fell about 25–34 events an hour vs 10 on placebo in two NEJM trials. What it means, the Zepbound comparison, and timing.
What If Being Short on Time Wrecks Your Diet Before You Open the Fridge?
Scarcity book summary in plain English: why being short on time makes a diet harder before you open the fridge, and four small fixes that build in slack.
His Bosses Said No to the Chip. He Built It Anyway, and Food Never Tasted the Same.
The Dorito Effect summary in plain English: why real food got bland, how fake flavor filled the gap, and one question to ask before you eat anything at all.
Same Junk Food, Same Calories. Only One Group of Mice Got Fat.
The Circadian Code summary in plain English: Satchin Panda's eating-window rule, the mouse and human studies, where it oversells, and a sample day to copy.
His Mother Did Everything Right. Her Blood Sugar Kept Rising. He Blamed the 9 p.m. Tea.
The Circadian Diabetes Code summary in plain English: the 10-hour eating rule, the studies behind it, a sample day to copy, and where the science falls short.
Her Doctors Planned to Remove Her Colon. A Heart Doctor Said: Quit Bread First.
Wheat Belly summary in plain English: the three big claims, the one that holds up, where scientists push back, and a seven-day wheat test you can run yourself.
She Ate Less Than Her Friends and Gained More. So She Read a Thousand Studies.
The Secret Life of Fat summary in plain English: why your body fights to keep its fat, the leptin bill after a diet, and a one-day plan that works with it.
I Had a Zero Grain Diet for 1 Day. Here’s What Happened
I tried a zero grain diet for one day. What I ate, what my glucose monitor and scale showed the next morning, and what the research says about cutting grains.
In 1999, a Kraft Executive Warned the Food Giants. They Didn’t Listen.
Salt Sugar Fat summary in plain English: how food giants tune sugar, fat and salt to keep you eating, a three-minute shelf test, and where the book falls short.
I Tried Prolon’s 5-Day Fast on a GLP-1. I Quit on Day 3.
I tried the Prolon fasting mimicking diet while on a GLP-1 to break a plateau. I quit on day 3 and gained weight. What went wrong, and what to do first.
He Passed His Stress Test. His Arteries Were 87 Years Old.
Beat the Heart Attack Gene summary in plain English: why a normal stress test can miss artery plaque, five things to check, and where the book oversells.
Retatrutide vs EloraTZP: 28.3% vs 23.3% Weight Loss, Compared (2026)
Retatrutide vs EloraTZP: 28.3% weight loss at 80 weeks vs 23.3% at 48. A plain-English comparison, the fair diabetes matchup, A1C, and side effects.
Magic Pill by Johann Hari: What Weight-Loss Drugs Can—and Cannot—Change
Johann Hari’s Magic Pill explores weight-loss drugs, our food environment, and the role food plays in our lives. A plain-English summary with evidence and limits.
Good Energy Book Summary: What to Keep, What to Question
Good Energy by Casey Means with Calley Means: the metabolic-health idea, the 93% statistic, glucose monitors, and everyday habits, with evidence in context.
Hooked by Michael Moss: How Food Giants Shape What We Eat
Michael Moss's Hooked shows how food companies shape cravings and repeated eating, with research on ultra-processed diets, addictive behavior, and industry influence.
Scientists Tested the Every-Other-Day Diet for a Year. Here’s What Happened
A plain-English summary of The Every-Other-Day Diet by Krista Varady with Bill Gottlieb: the book’s rules, later trials and practical trade-offs.
The Longevity Diet Book Summary: 7 Lessons on Food and Fasting
A plain-English look at ProLon, the five-day fasting-mimicking protocol, cell renewal, and Valter Longo's research.
The Telomere Effect Book Summary: 7 Useful Lessons
A plain-English summary of The Telomere Effect by Elizabeth Blackburn and Elissa Epel: seven lessons about habits, stress, and the limits of an aging marker.
Why We Sleep Book Summary: 6 Ideas Worth Taking to Bed
A plain-English summary of Why We Sleep by Matthew Walker: the useful parts, the overhyped parts, and one thing to try tonight.
12 Things to Eat and Do Every Day. Most People Miss Number 1.
A plain-English summary of How Not to Die by Dr. Michael Greger
The Pleasure Trap: Why Healthy Food Tastes Boring (and the 3-Week Fix)
A visual summary of Douglas Lisle and Alan Goldhamer’s book: why cravings aren’t a character flaw, how tastes can change, and ways to make healthier choices easier.
Prevent and Reverse Heart Disease: 7 Lessons From Dr. Esselstyn’s Book
A visual book summary of Dr. Caldwell B. Esselstyn Jr.’s plant-based program.
You Eat Too Fast. Catch It Before the Plate Is Empty.
Why rushed eating is so hard to notice, why most slow-eating advice feels like homework, and how MealCam gives you a gentle cue mid-meal.
Browse by subject

























































